





LEADING THE DEVELOPMENT OF MODERN MEDICINE

RESVERLOGIX CORP. (TSX:RVX) is a late-stage biotechnology company with a leadership position in **EPIGENETICS** - dedicated to improving the lives of patients with chronic illnesses

Full results from the Company's Phase 3 Clinical Trial – BETonMACE, studying lead drug candidate **APABETALONE** – will be presented during a late-breaking session at AHA on November 16th, 2019. The Company remains focused on three initial indications – acute coronary syndrome, vascular cognitive dementia and chronic kidney disease – with an addressable market of over 12 million patients in the top 8 markets



APABETALONE - BET INHIBITOR FOR THE REDUCTION OF MACE




✉ : ir@resverlogix.com
 ☎ : 403.254.9252
 🌐 : www.resverlogix.com
 🐦 : @Resverlogix_RVX

TSX:RVX



THE FUTURE OF DRUG DEVELOPMENT




Epigenetics

While most people are familiar with the inheritance of genes via DNA from one generation to the next, the activity of these genes is actually determined by epigenetics, which literally means "on top of" genetics. DNA is considered the hardware of the human body, while epigenetics can be referred to as the software. DNA contains the code that tells our cells what to do, and this coded message is the same in every cell and does not change with time. However, our cells do not behave in the exact same way across time, particularly when disease is involved. Epigenetic changes to the DNA allow the message in the genes to be turned up or down like a dimmer switch, telling the cells which products to make more, or less of. During this process the DNA is not altered. The epigenetic control over the genetic message in the DNA underlies many diseases, and for this reason, epigenetics has become an exciting forefront for the discovery of new medicines.

APABETALONE CLINICAL TRIAL HISTORY

Completed Trials

Current and Planned Trials



BETonMACE Overview

- **Q4 2015:** Phase 3 **BETonMACE** trial commenced in high-risk cardiovascular disease patients with T2 diabetes mellitus and low HDL.
- **Primary endpoint:** time to first occurrence of a Major Adverse Cardiac Event (MACE).
- **Q1 2018:** **BETonMACE** exceeded full enrollment with 2,425 study participants.
- **Q2 2019:** **BETonMACE** successfully reached its targeted 250 MACE events bringing the trial closer to completion.
- **BETonMACE** has been reviewed 9 times during the trial by an independent Data and Safety Monitoring Board, with no safety issues identified.

News Highlights

Analysts

Financial Profile

Sep. 30, 2019 - Resverlogix Announces Topline Results in BETonMACE Phase 3 Epigenetics Trial

Roth Capital Partners: Jerry Isaacson, PhD

- Shares O/S (MM): ~209
- Share Price: \$1.25
- Market Cap (MM): ~\$180
- 52 week low/high: \$0.34/\$4.94
- Total Cash Raised (MM): ~\$515

Sep. 23, 2019 - Resverlogix Announces BETonMACE Trial Results Accepted for Presentation at AHA's Scientific Sessions 2019

Van Leeuwenhoeck Research: Marcel Wijma, MSc

Zacks: John Vandermosten, CFA

Upcoming Events

Aug. 22, 2019 - RVX Announces Annual and Special Meeting of Shareholders set for October 31, 2019

Nov. 16-18, 2019 - American Heart Association Scientific Sessions, Philadelphia, PA

July 8, 2019 - RVX Announces BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits

Dec. 4-7, 2019 - 12th Clinical Trials on Alzheimer's Disease Conference, San Diego, CA

Notes:
*As at 02-OCT-2019
*All figures in CAD\$